After upregulation, FZD10 promotes self-renewal of hepatic CSCs by activating β-catenin and YAP1; it also reduces HCC cell sensitivity to lenvatinib by activating the β-catenin/c-Jun/MEK/ERK axis. The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.